Medtronic Plc (Medtronic), manufactures and commercializes products for cardiac rhythm management, spinal, neuromodulation, cardiovascular, diabetes and minimally invasive and surgical procedures.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Medtronic's R&D initiatives are focused on maintaining or achieving technological leadership in the markets it serves. The company is committed to developing technological enhancements and new indications for existing products, and less invasive and new technologies for new and emerging markets to address unmet patient needs. The company's R&D activities include improving existing products and therapies, expanding its indications and applications for use, developing new therapies and procedures, and entering into arrangements with third parties to fund the development of certain technologies. The company also focuses on optimizing innovation, improving R&D productivity, driving growth in emerging markets, generating clinical evidence, and assessing R&D programs based on its ability to address unmet clinical needs, produce better patient outcomes, and create new standards of care. The Medtronic Engineering and Innovation Center (MEIC) is a key R&D unit of Medtronic. The unit's role is to generate innovative solutions for global healthcare. The center focuses on R&D innovation with multiple business units globally across the areas of embedded and enterprise software, product security, data engineering, systems engineering, mechanical and hardware design, and quality and regulatory. The MEIC also collaborates closely with the Medtronic commercial team in India, promoting strategic and long-term partnerships with key opinion leaders, academic institutions, and hospital networks across the country. The company operates one R&D center, the Medtronic Engineering and Innovation Center (MEIC), located in Hyderabad, India. It has contributed to over 200 patents and 500 plus Intellectual Properties disclosures globally. The company's pipeline products include the Hugo RAS system, the adoption of AI in Endoscopy, Signia powered stapling devices, next-gen Ligasure and Sonicision vessel sealing devices, hemorrhagic stroke intravascular device, and next-generation spine enabling technologies. The company has entered into exclusive and non-exclusive licenses relating to a wide array of third-party technologies. As of April 2025, the company owned 35 labs and research development sites. In FY2025, Medtronic had 191 active clinical trials and over 43,000 active patent matters. In FY2025, the company spent US$2,732 million on its R&D activities, which as a percentage of revenue stood at 8.1%.